New Delhi, 11 September (IANS). The Technology Development Board (TDB) under the Department of Science and Technology has supported a startup in Hyderabad for the treatment of pneumonia and antimicrobial resistance (AMR). The ministry gave this information on Thursday.
The indigenous antibiotic nebulization suspension for pneumonia (AONEUM-04), (transports antibiotics to the body effectively represents a revolutionary change and also targets AMR. ‘AODH LifeSyins’ will make it in collaboration with TDB. This technology is in line with Prime Minister Narendra Modi’s self -reliant India’s view. Which will be able to establish India as a global leader in healthcare technology.
The ministry said, “Separated from oral or intravenous therapy, AONEUM-04 will directly transport antibiotics to the infected part through nebulization, which will also reduce the risk of side effects.”
In addition, its unique formulation, sustand release (the drug distribution system that gradually releases the drug at a prescribed rate), strong mucocaidhations (pharmaceutical content sticks to mucosa, which increases the time of entry and effect of the drug to the body) and biofilm discharge capabilities, which increases the expectation of the expected results and the expected results are expected. Is.
The ministry said, “This makes it particularly relevant to India, where pneumonia is a major cause of child mortality and AMR is a rapid emerging healthcare crisis.”
With a proven ability to improve treatment compliance and strength, this technique raises hope not only for India, but also in global markets.
TDB Secretary Rajesh Kumar Pathak said, “This project can be seen as an important stage in dealing with two serious health challenges, pneumonia and antimicrobial resistance in India and the world. The AONEUM -04 is supported by supporting TDB and globally relevant health solution.
This innovation has successfully crossed pre-clinical trials and will pass through the clinical trial phase III before commercialization.
“With the support of TDB, we are ready to pursue AONEUM-04 through the final clinical trial and really bring patient-focused antibiotic medicine to the market.
-IANS
KR/
